Cyclerion Therapeutics, Inc.

NasdaqCM:CYCN Stock Report

Market Cap: US$14.5m

Cyclerion Therapeutics Future Growth

Future criteria checks 0/6

Cyclerion Therapeutics's revenue and earnings are forecast to decline at 162.1% and 49.5% per annum respectively while EPS is expected to grow by 22.1% per annum.

Key information

-49.5%

Earnings growth rate

22.11%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth rate-162.1%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Feb 2026

Recent future growth updates

Recent updates

Seeking Alpha • Oct 06

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Cyclerion Therapeutics (NASDAQ:CYCN) on Thursday said it would reduce its workforce by about 45% as part of a strategic prioritization to focus its resources on the development of its therapy CY6463 for the treatment of mitochondrial diseases. Shares of the micro-cap clinical-stage biopharma slumped 32% to $0.64 in morning trading. CYCN said it expects to take a one-time charge related to the workforce reduction of about $1.9M that would be incurred primarily in Q4 2022. The company will first concentrate its development of CY6463 for MELAS, which is a mitochondrial disease that primarily affects the nervous system and muscles. CYCN plans to meet with the U.S. FDA in Q4 to discuss the MELAS development program. The company also said it intends to leverage its other clinical assets through licensing agreements and partnership.
Analysis Article • Aug 09

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Mar 03

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 26

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration. Cyclerion has upcoming phase 2 data coming out in H12022 that will be a major inflection point to potentially open up new opportunities for the distressed company. As a result, the company is one to monitor over the next few months and wait to potentially buy the stock after new clinical data is reported.
Seeking Alpha • Jun 21

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

After two candidate failures over the past two years, Cyclerion Therapeutics, Inc. is pinning its hopes on CNS therapy CY6463. The soluble guanylate cyclase modulator is currently undergoing mid-stage evaluation for one CNS indication and should enter a Phase 2 study for another in 2021. With a small market cap and no clinical data due until YE21, yet significant insider buying from the CEO, this busted IPO merited a deeper dive. A full investment analysis is provided in the paragraphs below.
Analysis Article • Mar 09

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Analysis Article • Jan 28

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

A look at the shareholders of Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) can tell us which group is most powerful...
Analysis Article • Dec 20

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

The last three months have been tough on Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) shareholders, who have seen the...

Earnings and Revenue Growth Forecasts

NasdaqCM:CYCN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-15N/AN/A1
12/31/2026N/A-12N/AN/A1
3/31/20262-5-4-4N/A
12/31/20252-4-3-3N/A
9/30/20253-2-1-1N/A
6/30/20252-2-3-3N/A
3/31/20252-3-3-3N/A
12/31/20242-3-4-4N/A
9/30/20240-5-6-6N/A
6/30/2024N/A-10-11-11N/A
3/31/2024N/A-11-17-17N/A
12/31/2023N/A-13-21-21N/A
9/30/2023N/A-15-27-27N/A
6/30/2023-13-30-30N/A
3/31/20230-8-34-34N/A
12/31/20220-18-41-41N/A
9/30/20221-25-42-42N/A
6/30/20222-48-40-40N/A
3/31/20225-51-35-35N/A
12/31/20214-52-37-37N/A
9/30/20214-60-42-42N/A
6/30/20214-68-49-49N/A
3/31/20211-71-58-58N/A
12/31/20202-78-74-72N/A
9/30/20204-85-82-81N/A
6/30/20205-93-92-89N/A
3/31/20206-106-104-97N/A
12/31/20195-123N/A-102N/A
9/30/20193-128N/A-103N/A
6/30/20192-130N/A-105N/A
3/31/2019N/A-127N/A-105N/A
12/31/2018N/A-115N/A-98N/A
9/30/2018N/A-112N/A-100N/A
6/30/2018N/A-108N/A-95N/A
3/31/2018N/A-99N/A-90N/A
12/31/2017N/A-94N/A-81N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYCN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYCN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYCN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYCN is forecast to have no revenue next year.

High Growth Revenue: CYCN is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CYCN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 05:20
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cyclerion Therapeutics, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pete StavropoulosCantor Fitzgerald & Co.
Joon So LeeTruist Securities
David BautzZacks Small-Cap Research